For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

Abstract Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin
inhibitor, has found increasing utilization as a heparin alternative in the pediatric population …

Background The optimal anticoagulant for patients with acute coronary syndrome treated
with percutaneous coronary intervention (PCI) has not been validated in current practice of …

Background Individual randomized controlled trials (RCTs) of periprocedural
anticoagulation with bivalirudin versus heparin during percutaneous coronary intervention …

The selection of antithrombotic strategies continue to be of utmost importance during
percutaneous coronary intervention (PCI) and have evolved over the past 40 years …

Heparin is stored endogenously within the secretory granules of basophils and mast cells,
and is only released into the vasculature at sites of injury. At these sites, it helps maintain …

Abstract Background/purpose Numerous GPIs are available for PCI. Although they were
tested in randomized controlled trials, a comparison between the different GPI strategies is …

Aim The purpose of our study was to evaluate the relative impact of bivalirudin on bleeding
outcomes associated with trans-radial interventions (TRI) in real world practice. Methods …

Bivalirudin is a direct thrombin inhibitor used during percutaneous coronary intervention
(PCI). Treatment with bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors …

Objectives: The aim of this study was to compare bivalirudin with heparin as anticoagulant
agents in patients with ST-segment elevation myocardial infarction treated with radial …